YEAR-LONG CLENBUTEROL TREATMENT OF MICE INCREASES MASS, BUT NOT SPECIFIC FORCE OR NORMALIZED POWER, OF SKELETAL MUSCLES
dc.contributor.author | Lynch, Gordon S. | en_US |
dc.contributor.author | Hinkle, Richard T. | en_US |
dc.contributor.author | Faulkner, John A. | en_US |
dc.date.accessioned | 2010-06-01T22:30:42Z | |
dc.date.available | 2010-06-01T22:30:42Z | |
dc.date.issued | 1999-02 | en_US |
dc.identifier.citation | Lynch, Gordon S; Hinkle, Richard T; Faulkner, John A (1999). "YEAR-LONG CLENBUTEROL TREATMENT OF MICE INCREASES MASS, BUT NOT SPECIFIC FORCE OR NORMALIZED POWER, OF SKELETAL MUSCLES." Clinical and Experimental Pharmacology and Physiology 26(2): 117-120. <http://hdl.handle.net/2027.42/75497> | en_US |
dc.identifier.issn | 0305-1870 | en_US |
dc.identifier.issn | 1440-1681 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/75497 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10065331&dopt=citation | en_US |
dc.format.extent | 37971 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Pty | en_US |
dc.rights | 1999 Blackwell Science Asia Pty. Ltd. | en_US |
dc.subject.other | Β 2 -Adrenoceptor Agonists | en_US |
dc.subject.other | Clenbuterol | en_US |
dc.subject.other | Contractile Properties | en_US |
dc.subject.other | Force | en_US |
dc.subject.other | Power | en_US |
dc.subject.other | Skeletal Muscle | en_US |
dc.title | YEAR-LONG CLENBUTEROL TREATMENT OF MICE INCREASES MASS, BUT NOT SPECIFIC FORCE OR NORMALIZED POWER, OF SKELETAL MUSCLES | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbsecondlevel | Physiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Institute of Gerontology and Departments of Physiology and Biomedical Engineering, The University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.identifier.pmid | 10065331 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/75497/1/j.1440-1681.1999.03001.x.pdf | |
dc.identifier.doi | 10.1046/j.1440-1681.1999.03001.x | en_US |
dc.identifier.source | Clinical and Experimental Pharmacology and Physiology | en_US |
dc.identifier.citedreference | Kim YS & Sainz RD. Β-Adrenergic agonists and hypertrophy of skeletal muscles. Life Sci. 1992; 50: 397 – 407. | en_US |
dc.identifier.citedreference | Carter WJ, Dang AQ, Faas FA, Lynch ME. Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. Metabolism 1991; 40: 855 – 60. | en_US |
dc.identifier.citedreference | Agbenyega ET & Wareham AC. Effect of clenbuterol on normal and denervated muscle growth and contractility. Muscle Nerve 1990; 13: 199 – 203. | en_US |
dc.identifier.citedreference | Maltin CA, Hay SM, Delday MI, Smith FG, Lobley GE, Reeds PJ. Clenbuterol, a beta-agonist, induces growth in innervated and denervated rat soleus muscle via apparently different mechanisms. Biosci. Rep. 1987; 7: 525 – 32. | en_US |
dc.identifier.citedreference | Zeman RJ, Ludemann R, Etlinger JD. Clenbuterol, a Β 2 -agonist, retards atrophy in denervated muscles. Am. J. Physiol. 1987; 252: E152 – 5. | en_US |
dc.identifier.citedreference | Delday MI & Maltin CA. Clenbuterol increases the expression of myogenin but not MyoD in immobilized rat muscles. Am. J. Physiol. 1997; 35: E941 – 4. | en_US |
dc.identifier.citedreference | Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by Β 2 -adrenoceptor activation. Am. J. Physiol. 1992; 26: E50 – 6. | en_US |
dc.identifier.citedreference | Moore NG, Pegg GG, Sillence MN. Anabolic effects of the Β 2 -adrenoceptor agonist salmeterol are dependent on route of administration. Am. J. Physiol. 1994; 267: E475 – 84. | en_US |
dc.identifier.citedreference | Maltin CA, Delday MI, Watson JS et al. Clenbuterol, a Β-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin. Sci. 1993; 84: 651 – 4. | en_US |
dc.identifier.citedreference | Zeman RJ, Zhang Y, Etlinger JD. Clenbuterol, a Β 2 -agonist, retards wasting and loss of contractility in irradiated dystrophic mdx muscle. Am. J. Physiol. 1994; 267: C865 – 8. | en_US |
dc.identifier.citedreference | Jones NL, McCartney N, McComas AJ. Human Muscle Power. Human Kinetics Publishers Inc., Champaign, IL. 1986. | en_US |
dc.identifier.citedreference | Dupont-Versteegden EE, Katz MS, McCarter RJ. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle Nerve 1995; 18: 1447 – 59. | en_US |
dc.identifier.citedreference | 13 National Institutes of Health. Guide for the Care and Use of Laboratory Animals. Office of Science and Health Reports. Public Health Service Publication No. 86-23, Bethesda, MD. 1985. | en_US |
dc.identifier.citedreference | Yang YT & McElligott MA. Multiple actions of Β 2 -adrenergic agonists on skeletal muscle and adipose tissue. Biochem. J. 1989; 261: 1 – 10. | en_US |
dc.identifier.citedreference | Hayes A & Williams DA. Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice. Clin. Exp. Pharm. Physiol. 1994; 21: 757 – 65. | en_US |
dc.identifier.citedreference | Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibres caused by clenbuterol, a Β 2 -receptor agonist. Am. J. Physiol. 1988; 254: E726 – 32. | en_US |
dc.identifier.citedreference | Lynch GS, Hayes A, Campbell SP, Williams DA. Effects of Β 2 -agonist administration and exercise on contractile activation of skeletal muscle fibers. J. Appl. Physiol. 1996; 81: 1610 – 18. | en_US |
dc.identifier.citedreference | Lynch GS, Rafael JA, Hinkle RT et al. Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. Am. J. Physiol. 1997; 272: C2063 – 8. | en_US |
dc.identifier.citedreference | Brooks SV & Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. J. Physiol. 1988; 404: 71 – 82. | en_US |
dc.identifier.citedreference | Brooks SV, Faulkner JA, McCubbery DA. Power outputs of slow and fast skeletal muscles of mice. J. App. Physiol. 1990; 68: 1282 – 5. | en_US |
dc.identifier.citedreference | Maltin CA, Delday MI, Reeds PJ. The effect of a growth promoting drug, clenbuterol, on fiber frequency and area in hind limb muscles from young male rats. Biosci. Rep. 1986; 6: 293 – 9. | en_US |
dc.identifier.citedreference | Torgan CE, Etgen GJ, Kang HY, Ivy JL. Fiber type-specific effects of clenbuterol and exercise training on insulin-resistant muscle. J. Appl. Physiol. 1995; 79: 163 – 7. | en_US |
dc.identifier.citedreference | Dodd SL, Powers SK, Vrabas I, Criswell D, Stetson S, Hussain R. Effects of clenbuterol on contractile and biochemical properties of skeletal muscle. Med. Sci. Sports Exer. 1996; 28: 669 – 76. | en_US |
dc.identifier.citedreference | Murphy RJL, BÉliveau L, Seburn KL, Gardiner PF. Clenbuterol has a greater influence on untrained than on previously trained skeletal muscle in rats. Eur. J. Appl. Physiol. 1996; 73: 304 – 10. | en_US |
dc.identifier.citedreference | MacLennan PA & Edwards RHT. Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle Β-adrenoceptors to induce hypertrophy. Biochem. J. 1989; 264: 573 – 9. | en_US |
dc.identifier.citedreference | Prather ID, Brown DE, North P, Wilson JR. Clenbuterol: A substitute for anabolic steroids. Med. Sci. Sports Exerc. 1995; 27: 1118 – 21. | en_US |
dc.identifier.citedreference | Hill AV. The dimensions of animals and their muscular dynamics. Proc R. Inst. Gt Br. 1950; 34: 450 – 71. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.